Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03196557 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject

A Phase 1 study of Immunoscience, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
2
Study locations

NCT03196557: Completed Phase 1 study of Immunoscience, sponsored by Bristol-Myers Squibb.

NCT03196557 is a Phase 1 study of Immunoscience that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03196557, a Phase 1 study of Immunoscience, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to assess the pharmacodynamics of Prednisolone in healthy male subjects

Primary Outcome

As measured by flow cytometry

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Prenisolone

Study Locations (2)

Texas

  • Ppd Development - Austin
  • Local Institution - Austin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-03-31
Est. Completion 2008-05-05
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT03196557 record still lists

NCT03196557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).

The record links to 1 condition, with Immunoscience appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03196557 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03196557 about?

NCT03196557 is a clinical study titled "A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject". The purpose of this study is to assess the pharmacodynamics of Prednisolone in healthy male subjects

What is the current status of trial NCT03196557?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-03-31. Estimated completion is 2008-05-05.

What conditions does trial NCT03196557 study?

This clinical trial studies the following conditions: Immunoscience.

What interventions are being tested in trial NCT03196557?

The interventions under investigation include: Placebo (DRUG), Prenisolone (DRUG).

Who is sponsoring clinical trial NCT03196557?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03196557 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03196557's enrollment target sits among peer trials

24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03196557, the US trial registry maintained by the National Library of Medicine. NCT03196557 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.